Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains.
暂无分享,去创建一个
J. Musser | S. Sreevatsan | A. Podbielski | M. Woischnik | S. Lukomski | W. Reichardt | C. Amberg | Andreas Podbielski | J. M. Musser | Werner Reichardt | Slawomir Lukomski
[1] J. Musser. Streptococcal superantigen, mitogenic factor, and pyrogenic exotoxin B expressed by Streptococcus pyogenes. Structure and function. , 1997, Preparative biochemistry & biotechnology.
[2] R. Kaul,et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G , 1996, Infection and immunity.
[3] A. Podbielski,et al. What is the size of the group A streptococcal vir regulon? The Mga regulator affects expression of secreted and surface virulence factors , 1996, Medical Microbiology and Immunology.
[4] J. Musser,et al. Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology. , 1996, Trends in microbiology.
[5] A. M. Marciel,et al. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease , 1996, Infection and immunity.
[6] H. Kuramitsu,et al. Role of Porphyromonas gingivalis protease activity in colonization of oral surfaces , 1996, Infection and immunity.
[7] A. Podbielski,et al. Molecular characterization of group A streptococcal (GAS) oligopeptide permease (Opp) and its effect on cysteine protease production , 1996, Molecular microbiology.
[8] L. Björck,et al. Streptococcal cysteine proteinase releases kinins: a virulence mechanism , 1996, The Journal of experimental medicine.
[9] J. Musser,et al. Substitution of cysteine 192 in a highly conserved Streptococcus pyogenes extracellular cysteine protease (interleukin 1beta convertase) alters proteolytic activity and ablates zymogen processing , 1996, Infection and immunity.
[10] J. Musser,et al. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci , 1996, Infection and immunity.
[11] T. File,et al. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] P. Carmeliet,et al. Generation and characterization of urokinase receptor-deficient mice. , 1996, The Journal of clinical investigation.
[13] J. Potempa,et al. Porphyromonas gingivalis: a proteinase/gene accounting audit. , 1995, Trends in microbiology.
[14] J. Musser,et al. Different forms of streptolysin O produced by Streptococcus pyogenes and by Escherichia coli expressing recombinant toxin: cleavage by streptococcal cysteine protease , 1995, Infection and immunity.
[15] A. Shaw,et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. , 1995, Immunity.
[16] L. Björck,et al. Streptococcal Cysteine Proteinase Releases Biologically Active Fragments of Streptococcal Surface Proteins (*) , 1995, The Journal of Biological Chemistry.
[17] H. Fletcher,et al. Virulence of a Porphyromonas gingivalis W83 mutant defective in the prtH gene , 1995, Infection and immunity.
[18] J. Musser,et al. Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease , 1995, Infection and immunity.
[19] R. Kamen,et al. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock , 1995, Cell.
[20] J. Musser,et al. Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface. , 1994, The Journal of biological chemistry.
[21] J. Musser,et al. Non‐congruent relationships between variation in emm gene sequences and the population genetic structure of group A streptococci , 1994, Molecular microbiology.
[22] J. Musser,et al. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. , 1994, Microbial pathogenesis.
[23] K. Gase,et al. Inactivation of the streptokinase gene prevents Streptococcus equisimilis H46A from acquiring cell-associated plasmin activity in the presence of plasminogen. , 1994, FEMS microbiology letters.
[24] J. Musser,et al. A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. , 1993, Microbial pathogenesis.
[25] M. Chaussee,et al. Inactivation of the streptococcal erythrogenic toxin B gene (speB) in Streptococcus pyogenes , 1993, Infection and immunity.
[26] J. Musser,et al. Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[27] B. Schwartz,et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome , 1993, Infection and immunity.
[28] D. Musher,et al. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). , 1993, The Journal of infectious diseases.
[29] J. Joseph,et al. Novel streptococcal-integration shuttle vectors for gene cloning and inactivation. , 1992 .
[30] Dwight R. Johnson,et al. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. , 1992, The Journal of infectious diseases.
[31] B. Schwartz,et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] S. Holm,et al. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. , 1992, The Journal of infectious diseases.
[33] J. Musser,et al. Characterization and clonal distribution of four alleles of the speA gene encoding pyrogenic exotoxin A (scarlet fever toxin) in Streptococcus pyogenes , 1991, The Journal of experimental medicine.
[34] J. Goldberg,et al. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[35] J. Musser,et al. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Ferretti,et al. Frequency of the erythrogenic toxin B and C genes (speB and speC) among clinical isolates of group A streptococci , 1991, Infection and immunity.
[37] P. Schlievert,et al. Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor , 1990, Journal of bacteriology.
[38] I. Olafsson,et al. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor , 1989, Nature.
[39] S. Twining. Fluorescein isothiocyanate-labeled casein assay for proteolytic enzymes. , 1984, Analytical biochemistry.
[40] H. Knöll,et al. Isolation and characterization of erythrogenic toxins. V. Communication: identity of erythrogenic toxin type B and streptococcal proteinase precursor. , 1983, Zentralblatt fur Bakteriologie, Mikrobiologie und Hygiene. 1. Abt. Originale A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie = International journal of microbiology and hygiene. A, Medical microbiology, infectious....
[41] R. Kessler,et al. Growth characteristics of group A streptococci in a new chemically defined medium , 1980, Infection and immunity.
[42] C. A. Ogburn,et al. The determination of streptococcal antiproteinase titers in sera of patients with rheumatic fever and streptococcal infection. , 1958, Journal of immunology.
[43] C. A. Ogburn,et al. EXTRACELLULAR ANTIGENS IN STEADY-STATE CULTURES OF THE HEMOLYTIC STREPTOCOCCUS: PRODUCTION OF PROTEINASE AT LOW pH , 1958, Journal of Bacteriology.
[44] A. Kellner,et al. MYOCARDIAL NECROSIS PRODUCED IN ANIMALS BY MEANS OF CRYSTALLINE STREPTOCOCCAL PROTEINASE , 1954, The Journal of experimental medicine.
[45] E. W. Todd. A STUDY OF THE INHIBITION OF STREPTOCOCCAL PROTEINASE BY SERA OF NORMAL AND IMMUNE ANIMALS AND OF PATIENTS INFECTED WITH GROUP A HEMOLYTIC STREPTOCOCCI , 1947, The Journal of experimental medicine.
[46] S. Elliott. A PROTEOLYTIC ENZYME PRODUCED BY GROUP A STREPTOCOCCI WITH SPECIAL REFERENCE TO ITS EFFECT ON THE TYPE-SPECIFIC M ANTIGEN , 1945, The Journal of experimental medicine.
[47] E. Hendry,et al. THE IMMUNISING ACTIVITY OF CERTAIN CHEMICAL FRACTIONS ISOLATED FROM HÆMOLYTIC STREPTOCOCCI , 1937 .
[48] J. Musser,et al. 6 The revival of group A streptococcal diseases, with a commentary on staphylococcal toxic shock syndrome , 1998 .
[49] J. Musser,et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. , 1997, JAMA.
[50] P. Rosenthal,et al. The proteases and pathogenicity of parasitic protozoa. , 1993, Annual review of microbiology.
[51] J. Ferretti,et al. Novel streptococcal-integration shuttle vectors for gene cloning and inactivation. , 1992, Gene.